I. Novel HCV NS5B polymerase inhibitors: Discovery of indole 2-carboxylic acids with C3-heterocycles

被引：46

作者：

Anilkumar, Gopinadhan N. ^{[1
]}

Lesburg, Charles A. ^{[1
]}

Selyutin, Oleg ^{[1
]}

Rosenblum, Stuart B. ^{[1
]}

Zeng, Qingbei ^{[1
]}

Jiang, Yueheng ^{[1
]}

Chan, Tin-Yau ^{[1
]}

Pu, Haiyan ^{[1
]}

Vaccaro, Henry ^{[1
]}

Wang, Li ^{[1
]}

Bennett, Frank ^{[1
]}

Chen, Kevin X. ^{[1
]}

Duca, Jose ^{[1
]}

Gavalas, Stephen ^{[1
]}

Huang, Yuhua ^{[1
]}

Pinto, Patrick ^{[1
]}

Sannigrahi, Mousumi ^{[1
]}

Velazquez, Francisco ^{[1
]}

Venkatraman, Srikanth ^{[1
]}

Vibulbhan, Bancha ^{[1
]}

Agrawal, Sony ^{[1
]}

Butkiewicz, Nancy ^{[1
]}

Feld, Boris ^{[1
]}

Ferrari, Eric ^{[1
]}

He, Zhiqing ^{[1
]}

Jiang, Chuan-kui ^{[1
]}

Palermo, Robert E. ^{[1
]}

Mcmonagle, Patricia ^{[1
]}

Huang, H. -C. ^{[1
]}

Shih, Neng-Yang ^{[1
]}

Njoroge, George ^{[1
]}

Kozlowski, Joseph A. ^{[1
]}

机构：

[1] Merck Res Labs, Kenilworth, NJ 07033 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2011年 / 21卷 / 18期

关键词：

HCV; NS5B polymerase; HEPATITIS-C VIRUS; DEPENDENT RNA-POLYMERASE; CRYSTAL-STRUCTURE; INFECTION;

D O I：

10.1016/j.bmcl.2011.07.021

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

SAR development of indole-based palm site inhibitors of HCV NS5B polymerase exemplified by initial indole lead 1 (NS5B IC(50) = 0.9 mu M, replicon EC(50) > 100 mu M) is described. Structure-based drug design led to the incorporation of novel heterocyclic moieties at the indole C3-position which formed a bidentate interaction with the protein backbone. SAR development resulted in leads 7q (NS5B IC(50) = 0.032 mu M, replicon EC(50) = 1.4 mu M) and 7r (NS5B IC(50) = 0.017 mu M, replicon EC(50) = 0.3 mu M) with improved enzyme and replicon activity. (C) 2011 Elsevier Ltd. All rights reserved.

引用

页码：5336 / 5341

页数：6

共 50 条

[21] Structure-Activity Relationship (SAR) Development and Discovery of Potent Indole-Based Inhibitors of the Hepatitis C Virus (HCV) NS5B Polymerase
Chen, Kevin X.
Vibulbhan, Bancha
Yang, Weiying
Sannigrahi, Mousumi
Velazquez, Francisco
Chan, Tin-Yau
Venkatraman, Srikanth
Anilkumar, Gopinadhan N.
Zeng, Qingbei
Bennet, Frank
Jiang, Yueheng
Lesburg, Charles A.
Duca, Jose
Pinto, Patrick
Gayalas, Stephen
Huang, Yuhua
Wu, Wanli
Selyutin, Oleg
Agrawal, Sony
Feld, Boris
Huang, Hsueh-Cheng
Li, Cheng
Cheng, Kuo-Chi
Shih, Neng-Yang
Kozlowski, Joseph A.
Rosenblum, Stuart B.
Njoroge, F. George
JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (02) : 754 - 765
[22] 2-(3-Thienyl)-5,6-dihydroxypyrimidine-4-carboxylic acids as inhibitors of HCV NS5B RdRp
Pacini, Barbara
Avolio, Salvatore
Ercolani, Caterina
Koch, Uwe
Migliaccio, Giovanni
Narjes, Frank
Pacini, Laura
Tomei, Licia
Harper, Steven
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (21) : 6245 - 6249
[23] 2-Aryl-3-carbonylquinolones: Design, Synthesis and Biological Evaluation of Novel HCV NS5B Polymerase Inhibitors
Wang Shenfeng
Lin Jianping
He Peilan
Zuo Jianping
Long Yaqiu
ACTA CHIMICA SINICA, 2014, 72 (08) : 906 - 913
[24] Nucleotide Prodrugs of 2′-Deoxy-2′-spirooxetane Ribonucleosides as Novel Inhibitors of the HCV NS5B Polymerase
Jonckers, Tim H. M.
Vandyck, Koen
Vandekerckhove, Leen
Hu, Lili
Tahri, Abdellah
Van Hoof, Steven
Lin, Tse-I
Vijgen, Leen
Berke, Jan Martin
Lachau-Durand, Sophie
Stoops, Bart
Leclercq, Laurent
Fanning, Gregory
Samuelsson, Bertil
Nilsson, Magnus
Rosenquist, Asa
Simmen, Kenny
Raboisson, Pierre
JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (05) : 1836 - 1844
[25] Discovery of novel potent HCV NS5B polymerase non-nucleoside inhibitors bearing a fused benzofuran scaffold
Zhong, Min
Peng, Eric
Huang, Ningwu
Huang, Qi
Huq, Anja
Lau, Meiyen
Colonno, Richard
Li, Leping
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2018, 28 (05) : 963 - 968
[26] Discovery of proline sulfonamides as potent and selective hepatitis C virus NS5b polymerase inhibitors. Evidence for a new NS5b polymerase binding
Gopalsamy, Ariamala
Chopra, Rajiv
Lim, Kitae
Ciszewski, Gregory
Shi, Mengxiao
Curran, Kevin J.
Sukits, Steven F.
Svenson, Kristine
Bard, Joel
Ellingboe, John W.
Agarwal, Atul
Krishnamurthy, Girija
Howe, Anita Y. M.
Orlowski, Mark
Feld, Boris
O'Connell, John
Mansour, Tarek S.
JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (11) : 3052 - 3055
[27] The discovery and structure-activity relationships of pyrano[3,4-b]indole based inhibitors of hepatitis C virus NS5B polymerase
LaPorte, Matthew G.
Draper, Tandy L.
Miller, Lori E.
Blackledge, Charles W.
Leister, Lara K.
Amparo, Eugene
Hussey, Alison R.
Young, Dorothy C.
Chunduru, Srinivas K.
Benetatos, Christopher A.
Rhodes, Gerry
Gopalsamy, Ariamala
Herbertz, Torsten
Burns, Christopher J.
Condon, Stephen M.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (09) : 2968 - 2973
[28] Combination of pharmacophore hypothesis and molecular docking to identify novel inhibitors of HCV NS5B polymerase
Harikishore, Amaravadhi
Li, Enlin
Lee, Jia Jun
Cho, Nam-Joon
Yoon, Ho Sup
MOLECULAR DIVERSITY, 2015, 19 (03) : 529 - 539
[29] Combination of pharmacophore hypothesis and molecular docking to identify novel inhibitors of HCV NS5B polymerase
Amaravadhi Harikishore
Enlin Li
Jia Jun Lee
Nam-Joon Cho
Ho Sup Yoon
Molecular Diversity, 2015, 19 : 529 - 539
[30] Discovery of novel dialkyl substituted thiophene inhibitors of HCV by in silico screening of the NS5B RdRp
Louise-May, Shirley
Yang, Wengang
Nie, Xingtie
Liu, Dongmei
Deshpande, Milind S.
Phadke, Avinash S.
Huang, Mingjun
Agarwal, Atul
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (14) : 3905 - 3909

← 1 2 3 4 5 →